ClinicalTrials.gg
CompletedNCT06107439LIPOKINESUpdated Sep 16, 2026

Impact of Lipodystrophy on the Inflammatory State of Non-diabetic Dunnigan Reunion Island Subjects

An interventional study of Bood and urine sampling in Lipodystrophy and Dunnigan Syndrome, sponsored by Centre Hospitalier Universitaire de la Réunion. Completed at 1 site in Reunion. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.

Primary conditionLipodystrophy, Familial PartialRegistry: LipodystrophyReclassifiedWhy we changed it
Registry
Lipodystrophy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lipodystrophy, Familial Partial
Why
  1. The study's listed conditions name Lipodystrophy, Familial Partial, a narrower term within Lipodystrophy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre Hospitalier Universitaire de la Réunion · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Few data and small numbers affect the inflammatory profile of Dunnigan patients. The levels of certain pro-inflammatory biomarkers would be found higher in these subjects compared to control individuals. However, in these studies, several confounding factors were not taken into account such as smoking, an underlying chronic inflammatory disease such as diabetes and could limit the interpretation of the results. There is no other observation of the anti-inflammatory status of these patients.

02

Conditions studied

  • Lipodystrophy
  • Dunnigan Syndrome

Browse trials for

03

In context

Lipodystrophy, Familial Partial Reclassified

20 studies on the registry are indexed under Lipodystrophy, Familial Partial; 5 are open to participants now.

This study's enrollment of 64 is above the median of 16 across 14 interventional studies indexed under Lipodystrophy, Familial Partial.

Browse Lipodystrophy, Familial Partial studies →

Lead sponsor

Centre Hospitalier Universitaire de la Réunion is the lead sponsor of 141 studies on the registry; 37 are open to participants now.

Compared within Lipodystrophy, Familial Partial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lipodystrophy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subject (>18 years old) affected by partial Dunnigan lipodystrophy in the homozygous or heterozygous state (genetic search for the positive mutation carried out before inclusion in the study).
  • Person affiliated to or beneficiary of a social security scheme.
  • Free, informed and written consent signed by the participant and the investigator.

Exclusion criteria

Exclusion Criteria:

  • - Minor
  • Persons placed under judicial protection, person participating in another research including a period of exclusion still in progress, severely impaired physical and/or psychological health, which, according to the investigator, may affect the participant's compliance with the study
  • Previous known diabetes
  • Pregnant woman
  • Woman who gave birth less than 6 months ago
  • Breastfeeding in progress
  • Participation in other research that may have an impact on the evaluation of the main judgment criteria
  • b level \< 7 mg/dl or \< 9-10 mg/dl for patients with cardiovascular or respiratory pathology.
  • Proven inflammatory pathologies
  • Anti-inflammatory treatment: taking in the last 3 months.
  • Active smoking
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Other
    sampling and clinical data collection

    Participant blood and urine are sampled for inflammatory signal analysis

    Biological: Bood and urine sampling

Interventions

  • BiologicalBood and urine sampling

    Bood and urine sampling

06

What researchers measure

Primary outcomes

  1. pro-inflammatory markers

    blood sample and dosage of pro inflammatory cytokine

    Time frame: inclusion day

07

Study locations

1 site
  • CHU La Réunion DRCI
    Saint-Pierre, 97400, Reunion
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Jul 2025, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Oct 30, 2023
StartActual
Aug 14, 2023
Primary completionActual
Jul 22, 2025
CompletionActual
Jul 22, 2025
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06107439
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Aug 14, 2023
Primary completion
Jul 22, 2025
Completion
Jul 22, 2025
Last update
Sep 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion